In3 Medical Device Summit
ROME
I would like to take the opportunity to introduce Medical Capital Advisors, one the sponsors of the In3 Conference in Rome in the month of April. We hope that you found the conference to be a valuable and interesting venue to present your company to potential funding sources and/or strategic partnerships. Medical Capital Advisors LLC (“MedCap”) is a leading specialized investment-banking advisor to the medical technology industry. The firm has successfully represented the financial interest of some the most sophisticated institutional investors and Fortune 500 companies in the world. Our current clients include leading medical technology firms in the largest sectors of medicine including orthopedic, cardiovascular, and biologics. We provide strategic advice relating to merger and acquisitions, strategic partnerships and capital investment opportunities.
Our clients can be assured that we at MedCap have the investment banking experience, knowledge and resources to understand your company’s technology, strategy and industry position. We have developed a network of relationships globally with strategic buyers so that we can offer our clients the benefit of insight and an appreciation for the kinds of deal structure that will fit with the company’s overall objectives. The Medical Capital Advisors team includes physicians, scientists, and business professionals, and senior investment bankers who work together to make sure that we understand the clinical aspects of your technology so that we can effectively position your company to create a value proposition that strategic acquirers and investors will appreciate.
April, 2007
———
PODCAST ALERT
The Future of Orthopedics: Episode 3
Ron Trahan, President and CEO of Ronald Trahan Associates (“RTA”) Inc., talks with Chris Velis, CEO of Medical Capital Advisors (www.medcapadvisors.com).The really hot technologies in orthopedics going forward? —There is ample evidence that there are five technology themes which are going to dominate the near-term future of orthopedics.Go to www.medtechmatters.com—After listening, you are then invited to post your comments about this podcast on our blog: www.medtechmatters.com/blog
PRESS RELEASE
March, 2007
———
In3 West Conference
IRVINE
Medtech Insight and Windhover Information’s prestigious “In3” investor conferences, announced today that Christopher Velis, its Chairman and CEO, will be the keynote speaker at MedTech Insight and Windhover Information’s upcoming In3 WEST investor conference, to be held at the Hyatt Regency, Irvine, Calif.
Velis will deliver his preconference address on Monday, Feb. 26, from 7:00–8:00 p.m. PT. Topics to be included in Velis’ address, “The State of Medtech Mergers, Acquisitions and IPOs in 2007,” will be:
•The current state. and near-term outlook, of M&A opportunities and public markets for device companies; and
•The current state. and near-term outlook, of Venture Capital and private Equity financing for device companies.
PRESS RELEASE
February 26, 2007
———
CerePedics
Medical Capital Advisors announced today that its client, CeraPedics, Inc., has closed on an $12.25 million private equity financing from OrbiMed Advisors, LLC (www.orbimed.com). Medical Capital Advisors served as investment banking advisor for CeraPedics.
Privately held CeraPedics (Lakewood, Colo.) is a medical device company working toward commercializing products for the orthopedic bone graft substitutes market based on its proprietary small peptide technology.
February 26, 2007
PRESS RELEASE
———
AAOS 2007 Reception
SAN DIEGO
Medical Capital Advisors hosted a reception during AAOS 2007 at the San Diego Museum of National History, showcasing emerging technology companies:
•Advanced Biomaterial Systems
•Arthrosurface, Inc.
•Biorthex, Inc.
•Harvest Technology
•MAKO Surgical Corp.
•Millenium Biologix Corp.
•Scandius BioMedical, Inc.
February 14, 2007
———
PODCAST ALERT
The Future of Orthopedics: Episode 1
The Future of Orthopedics: Episode 2
Ron Trahan, President and CEO of Ronald Trahan Associates (“RTA”) Inc., talks with Chris Velis, CEO of Medical Capital Advisors (www.medcapadvisors.com), who builds a strong case for why the large strategics are still willing to pay big prices for innovative technologies in the orthopedics sector in 2007.
Go to www.medtechmatters.com—After listening, you are then invited to post your comments about this podcast on our blog: www.medtechmatters.com/blog
February 8–12, 2007
PRESS RELEASE
———
Morris Innovative Research
FISH
Medical Capital Advisors announced today that it has been retained on an exclusive basis by Bloomington, Ind.-based Morris Innovative Research (MIR) to explore strategic alternatives for the emerging medical device company, including sale of the company.
Founded in 2002, MIR has developed the FISH (Femoral Introducer Sheath and Hemostasis) device, a biological vascular closure device (VCD) that does not leave foreign material at the vascular puncture (arteriotomy) site. The unique FISH device closes the femoral artery following an interventional or diagnostic endovascular procedure using SIS (small intestinal submucosal), a clinically proven, patented, and proprietary biologic material that completely remodels into native tissue.
January 24, 2007
PRESS RELEASE
———
N E W S
NEWS ARCHIVES
Served as exclusive
investment banking advisor to
in its acquisition by a subsidiary of
Press Release
November 2007
What people are saying:
THE WALL STREET JOURNAL
———
In3 East Conference
BOSTON
Medical Capital Advisors to present “The Future of Medical Technology”at Medtech Insight and Windhover Information’s In3 East conference, October 3–5, 2007 Westin Copley Place, Boston. Mr. Velis will deliver his address on Wednesday, Oct. 3, from 7:00–8:00 p.m.. Topics to be included in Velis’ address, “The Future of Medical Technology”, will be:
•The current state and near-term outlook of M&A opportunities and public markets for medical technology companies;
•The current state and near-term outlook of Venture Capital and Private Equity financing for medical technology companies;
•and,Today’s and tomorrow’s leading technologies, and how they will impact healthcare.
October 3–7, 2007
———
Medical Capital Group expands its medical technology investment-banking team with the addition of Hari V. Sundram, M.D., a board-certified specialist in anesthesiology and pain medicine.
“We are pleased that Dr. Sundram has joined Medical Capital Group, and we are looking forward to working with him. His clinical and medical knowledge will provide our firm’s clients with the deep knowledge and understanding that they need to develop exceptional medical devices for the advancement of healthcare delivery,” said Christopher J.P. Velis, Chairman and CEO of Medical Capital Group.
Dr. Sundram will serve as Vice President and Medical Director at Medical Capital Development, working in the business development group and facilitating the evolution of cutting-edge medical technologies into growth companies.Most recently, he has served as a pain specialist at Massachusetts General Hospital. Dr. Sundram is a member of the Scientific Advisory Board of Acumen Medical, an early-stage medical device firm developing catheters for the placement of leads in Bi-Ventricular pacemakers. Previously, Dr. Sundram co-founded ChemTracker Technologies. Dr. Sundram holds four device patents and has co-authored eight scientific papers.
He holds a bachelor of science degree from Wayne State University and graduated from Wayne State University School of Medicine. He also attended the University of Pennsylvania, the School of Anesthesiology and Critical Care. Dr. Sundram completed a pain fellowship at Massachusetts General Hospital/Harvard University.
September 24, 2007
———
Medical Capital Advisors expands its Medical Technology Investment-Banking Team with the addition of Andrew M. Streisfeld, CPA.
“Andy brings twenty-five years of investment banking and financial services experience to our firm. We are pleased to have him join us as a world class Chief Financial Officer.” said Christopher J.P. Velis, Chairman and CEO of Medical Capital Advisors.
Andrew M. Streisfeld, will serve as the Chief Financial Officer at Medical Capital Advisors. He served as Chief Financial Officer and Chief Operating Officer at Brown & Company Securities Corporation for 23 years. After Brown & Company he served as the Chief Financial Officer of a public software company. Mr. Streisfeld also held the position of Chief Executive Officer/Chief Financial Officer of a discount brokerage firm.
He holds a BA in biology from Hartwick College, Oneonta, New York, and a MS/MBA in accounting from Northeastern University Graduate School of Professional Accounting, Boston, MA. Mr. Streisfeld is a certified public accountant.
February 26, 2007
———
In3 Medical Device Summit
SAN FRANCISCO
Medical Capital Advisors to present “How to Destroy a Medtech Company and Fast: An Investment Banker’s Perspective,”
at Medtech Insight and Windhover Information’s In3 Medical Device Summit, June 3-5, 2007, at the Grand Hyatt San Francisco
June 3–5, 2007
PRESS RELEASE
———
Medical Capital Advisors announced today that it has further expanded its investment-banking team, effective immediately, with the addition of Tom Duquette and Denise I. Saltojanes.
Tom Duquette will serve as Managing Director of Private Placements at Medical Capital Advisors. Previously, Tom enjoyed a 16-year career as Senior Executive and Associate Director at Bear Stearns & Co. His experience included investment banking, private placements, merchant banking, institutional equities, block trading, derivatives, and hedging.
Tom graduated with honors from the University of Massachusetts at Amherst, earning a bachelor’s degree in Economics.
Denise Saltojanes, who will serve as Vice President of Investment Banking at Medical Capital Advisors, will be an integral part of the firm’s Merger and Acquisition team, where she will apply her background in medicine, science and finance. She was a process engineer with General Electric, and Senior Executive at a biopolymer research company in Cambridge, Mass. She has been involved in private financings for orthopedic device and other medical technology companies. Additionally, Denise has held positions at the Orthopedic Biomedical and Biomaterial Lab at Massachusetts General Hospital.
Denise holds a bachelor’s degree in Chemical Engineering from the University of New Hampshire, and she graduated magna cum laude with an MBA from Babson College.
May 15, 2007
PRESS RELEASE
———
